Eli Lilly Reports Phase 2 Data for Upadacitinib in Beta-thalassemia

Eli Lilly today announced Phase 2 results for upadacitinib in patients with beta-thalassemia. The study demonstrated that upadacitinib achieves clinical remission compared to standard of care or placebo. These results provide important insights into the treatment of beta-thalassemia and support the continued development of upadacitinib in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.